世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
脳腫瘍の診断と治療薬 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030Brain Tumor Diagnosis and Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 脳腫瘍は手術、放射線療法、化学療法で治療される。本レポートでは主に脳腫瘍診断・治療薬市場に焦点を当てています。 脳腫瘍の診断と治療薬の世界市場は、2023年に2億5,100万米ドルの価値があると推定され、202... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー脳腫瘍は手術、放射線療法、化学療法で治療される。本レポートでは主に脳腫瘍診断・治療薬市場に焦点を当てています。脳腫瘍の診断と治療薬の世界市場は、2023年に2億5,100万米ドルの価値があると推定され、2024年から2030年の予測期間中のCAGRは9.8%で、2030年までに4億6,857万米ドルの再調整規模になると予測されています。 脳腫瘍診断・治療薬の北米市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に年平均成長率%で、2030年までに100万ドルに達する見込みです。 脳腫瘍診断と治療薬のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達する見込みです。 脳腫瘍診断と治療薬のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に年平均成長率%で、2030年までに100万ドルに達する見込みです。 脳腫瘍診断および治療薬の世界的な主要企業には、GEヘルスケア、日立製作所、フィリップスヘルスケア、シーメンス・ヘルスニイヤーズ、株式会社東芝、富士フイルム株式会社、株式会社島津製作所、Merck & Co.、AstraZenecaなどがあります。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。 レポートの範囲 本レポートは、脳腫瘍診断・治療薬の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の脳腫瘍診断・治療薬の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。 脳腫瘍診断と治療薬の市場規模、推定、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供します。定量的および定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、脳腫瘍診断および治療薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 GEヘルスケア 日立製作所 フィリップスヘルスケア シーメンス・ヘルスイニアス 株式会社東芝 富士フイルム株式会社 株式会社島津製作所 メルク社 アストラゼネカ ブリストル・マイヤー・スクイブ ノバルティス ロシュ・ダイアグノスティックス タイプ別セグメント MRI CTスキャン 組織サンプリング PET-CTスキャン 脳動脈造影 腰椎穿刺 分子検査 脳波検査 用途別セグメント 手術 放射線療法 化学療法 免疫療法 標的療法 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章：報告書のスコープ、世界の総市場規模を紹介します。本章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章 脳腫瘍診断・治療薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章：地域レベルでの脳腫瘍診断と治療薬の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、市場規模を紹介しています。 第6章 国別脳腫瘍診断・治療薬の収益各国・地域のタイプ別、用途別のシグメイトデータを提供しています。 第7章：主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本状況を詳細に紹介。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Brain Tumor Diagnosis and Therapeutics Product Introduction 1.2 Global Brain Tumor Diagnosis and Therapeutics Market Size Forecast 1.3 Brain Tumor Diagnosis and Therapeutics Market Trends & Drivers 1.3.1 Brain Tumor Diagnosis and Therapeutics Industry Trends 1.3.2 Brain Tumor Diagnosis and Therapeutics Market Drivers & Opportunity 1.3.3 Brain Tumor Diagnosis and Therapeutics Market Challenges 1.3.4 Brain Tumor Diagnosis and Therapeutics Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Brain Tumor Diagnosis and Therapeutics Players Revenue Ranking (2023) 2.2 Global Brain Tumor Diagnosis and Therapeutics Revenue by Company (2019-2024) 2.3 Key Companies Brain Tumor Diagnosis and Therapeutics Manufacturing Base Distribution and Headquarters 2.4 Key Companies Brain Tumor Diagnosis and Therapeutics Product Offered 2.5 Key Companies Time to Begin Mass Production of Brain Tumor Diagnosis and Therapeutics 2.6 Brain Tumor Diagnosis and Therapeutics Market Competitive Analysis 2.6.1 Brain Tumor Diagnosis and Therapeutics Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Brain Tumor Diagnosis and Therapeutics Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Brain Tumor Diagnosis and Therapeutics as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 MRI 3.1.2 CT Scan 3.1.3 Tissue Sampling 3.1.4 PET-CT Scan 3.1.5 Cerebral Arteriogram 3.1.6 Lumbar Puncture 3.1.7 Molecular Testing 3.1.8 EEG 3.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type 3.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (2019-2030) 3.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Surgery 4.1.2 Radiation Therapy 4.1.3 Chemotherapy 4.1.4 Immunotherapy 4.1.5 Targeted Therapy 4.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application 4.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (2019-2030) 4.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region 5.1.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2019-2024) 5.1.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2025-2030) 5.1.4 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.2.2 North America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.3.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.4.2 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.5.2 South America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.6.2 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value 6.3 United States 6.3.1 United States Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.3.2 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.4.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.5.2 China Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.5.3 China Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.6.2 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.7.2 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.8.2 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.9.2 India Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.9.3 India Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 GE Healthcare 7.1.1 GE Healthcare Profile 7.1.2 GE Healthcare Main Business 7.1.3 GE Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.1.4 GE Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.1.5 GE Healthcare Recent Developments 7.2 Hitachi 7.2.1 Hitachi Profile 7.2.2 Hitachi Main Business 7.2.3 Hitachi Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.2.4 Hitachi Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.2.5 Hitachi Recent Developments 7.3 Philips Healthcare 7.3.1 Philips Healthcare Profile 7.3.2 Philips Healthcare Main Business 7.3.3 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.3.4 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.3.5 Siemens Healthineers Recent Developments 7.4 Siemens Healthineers 7.4.1 Siemens Healthineers Profile 7.4.2 Siemens Healthineers Main Business 7.4.3 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.4.4 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.4.5 Siemens Healthineers Recent Developments 7.5 Toshiba Corporation 7.5.1 Toshiba Corporation Profile 7.5.2 Toshiba Corporation Main Business 7.5.3 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.5.4 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.5.5 Toshiba Corporation Recent Developments 7.6 Fujifilm Corporation 7.6.1 Fujifilm Corporation Profile 7.6.2 Fujifilm Corporation Main Business 7.6.3 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.6.4 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.6.5 Fujifilm Corporation Recent Developments 7.7 Shimadzu Corporation 7.7.1 Shimadzu Corporation Profile 7.7.2 Shimadzu Corporation Main Business 7.7.3 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.7.4 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.7.5 Shimadzu Corporation Recent Developments 7.8 Merck & Co. 7.8.1 Merck & Co. Profile 7.8.2 Merck & Co. Main Business 7.8.3 Merck & Co. Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.8.4 Merck & Co. Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.8.5 Merck & Co. Recent Developments 7.9 AstraZeneca 7.9.1 AstraZeneca Profile 7.9.2 AstraZeneca Main Business 7.9.3 AstraZeneca Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.9.4 AstraZeneca Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.9.5 AstraZeneca Recent Developments 7.10 Bristol Myer Squibb 7.10.1 Bristol Myer Squibb Profile 7.10.2 Bristol Myer Squibb Main Business 7.10.3 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.10.4 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.10.5 Bristol Myer Squibb Recent Developments 7.11 Novartis 7.11.1 Novartis Profile 7.11.2 Novartis Main Business 7.11.3 Novartis Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.11.4 Novartis Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.11.5 Novartis Recent Developments 7.12 Roche Diagnostics 7.12.1 Roche Diagnostics Profile 7.12.2 Roche Diagnostics Main Business 7.12.3 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.12.4 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.12.5 Roche Diagnostics Recent Developments 8 Industry Chain Analysis 8.1 Brain Tumor Diagnosis and Therapeutics Industrial Chain 8.2 Brain Tumor Diagnosis and Therapeutics Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Brain Tumor Diagnosis and Therapeutics Sales Model 8.5.2 Sales Channel 8.5.3 Brain Tumor Diagnosis and Therapeutics Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryBrain tumors are treated with surgery, radiation therapy and chemotherapy. This report mainly focuses on brain tumor diagnosis and therapeutics market. Table of Contents1 Market Overview1.1 Brain Tumor Diagnosis and Therapeutics Product Introduction 1.2 Global Brain Tumor Diagnosis and Therapeutics Market Size Forecast 1.3 Brain Tumor Diagnosis and Therapeutics Market Trends & Drivers 1.3.1 Brain Tumor Diagnosis and Therapeutics Industry Trends 1.3.2 Brain Tumor Diagnosis and Therapeutics Market Drivers & Opportunity 1.3.3 Brain Tumor Diagnosis and Therapeutics Market Challenges 1.3.4 Brain Tumor Diagnosis and Therapeutics Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Brain Tumor Diagnosis and Therapeutics Players Revenue Ranking (2023) 2.2 Global Brain Tumor Diagnosis and Therapeutics Revenue by Company (2019-2024) 2.3 Key Companies Brain Tumor Diagnosis and Therapeutics Manufacturing Base Distribution and Headquarters 2.4 Key Companies Brain Tumor Diagnosis and Therapeutics Product Offered 2.5 Key Companies Time to Begin Mass Production of Brain Tumor Diagnosis and Therapeutics 2.6 Brain Tumor Diagnosis and Therapeutics Market Competitive Analysis 2.6.1 Brain Tumor Diagnosis and Therapeutics Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Brain Tumor Diagnosis and Therapeutics Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Brain Tumor Diagnosis and Therapeutics as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 MRI 3.1.2 CT Scan 3.1.3 Tissue Sampling 3.1.4 PET-CT Scan 3.1.5 Cerebral Arteriogram 3.1.6 Lumbar Puncture 3.1.7 Molecular Testing 3.1.8 EEG 3.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type 3.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (2019-2030) 3.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Surgery 4.1.2 Radiation Therapy 4.1.3 Chemotherapy 4.1.4 Immunotherapy 4.1.5 Targeted Therapy 4.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application 4.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (2019-2030) 4.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region 5.1.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2019-2024) 5.1.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2025-2030) 5.1.4 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.2.2 North America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.3.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.4.2 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.5.2 South America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 5.6.2 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value 6.3 United States 6.3.1 United States Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.3.2 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.4.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.5.2 China Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.5.3 China Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.6.2 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.7.2 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.8.2 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030 6.9.2 India Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030 6.9.3 India Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 GE Healthcare 7.1.1 GE Healthcare Profile 7.1.2 GE Healthcare Main Business 7.1.3 GE Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.1.4 GE Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.1.5 GE Healthcare Recent Developments 7.2 Hitachi 7.2.1 Hitachi Profile 7.2.2 Hitachi Main Business 7.2.3 Hitachi Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.2.4 Hitachi Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.2.5 Hitachi Recent Developments 7.3 Philips Healthcare 7.3.1 Philips Healthcare Profile 7.3.2 Philips Healthcare Main Business 7.3.3 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.3.4 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.3.5 Siemens Healthineers Recent Developments 7.4 Siemens Healthineers 7.4.1 Siemens Healthineers Profile 7.4.2 Siemens Healthineers Main Business 7.4.3 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.4.4 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.4.5 Siemens Healthineers Recent Developments 7.5 Toshiba Corporation 7.5.1 Toshiba Corporation Profile 7.5.2 Toshiba Corporation Main Business 7.5.3 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.5.4 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.5.5 Toshiba Corporation Recent Developments 7.6 Fujifilm Corporation 7.6.1 Fujifilm Corporation Profile 7.6.2 Fujifilm Corporation Main Business 7.6.3 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.6.4 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.6.5 Fujifilm Corporation Recent Developments 7.7 Shimadzu Corporation 7.7.1 Shimadzu Corporation Profile 7.7.2 Shimadzu Corporation Main Business 7.7.3 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.7.4 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.7.5 Shimadzu Corporation Recent Developments 7.8 Merck & Co. 7.8.1 Merck & Co. Profile 7.8.2 Merck & Co. Main Business 7.8.3 Merck & Co. Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.8.4 Merck & Co. Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.8.5 Merck & Co. Recent Developments 7.9 AstraZeneca 7.9.1 AstraZeneca Profile 7.9.2 AstraZeneca Main Business 7.9.3 AstraZeneca Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.9.4 AstraZeneca Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.9.5 AstraZeneca Recent Developments 7.10 Bristol Myer Squibb 7.10.1 Bristol Myer Squibb Profile 7.10.2 Bristol Myer Squibb Main Business 7.10.3 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.10.4 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.10.5 Bristol Myer Squibb Recent Developments 7.11 Novartis 7.11.1 Novartis Profile 7.11.2 Novartis Main Business 7.11.3 Novartis Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.11.4 Novartis Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.11.5 Novartis Recent Developments 7.12 Roche Diagnostics 7.12.1 Roche Diagnostics Profile 7.12.2 Roche Diagnostics Main Business 7.12.3 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions 7.12.4 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024) 7.12.5 Roche Diagnostics Recent Developments 8 Industry Chain Analysis 8.1 Brain Tumor Diagnosis and Therapeutics Industrial Chain 8.2 Brain Tumor Diagnosis and Therapeutics Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Brain Tumor Diagnosis and Therapeutics Sales Model 8.5.2 Sales Channel 8.5.3 Brain Tumor Diagnosis and Therapeutics Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
QYResearch社の医療分野での最新刊レポート
本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|